Agilon Health’s SWOT analysis: stock faces profitability pressures

Agilon Health, Inc. (NYSE:AGL) continues to navigate challenging waters as the healthcare services company reported its third quarter fiscal year 2025 results, revealing a complex picture of revenue growth tempered by significant profitability concerns. Despite these challenges, the stock has surged dramatically, trading at $87.31—near its 52-week high of $90.48—with a remarkable 576% return over the past six months. The company, which provides technology-enabled services to physician groups for value-based care, finds itself at a critical juncture as it manages relationships with major payors while attempting to stabilize its financial position.

Recent Financial Performance Reveals Mixed Results

The company’s third quarter fiscal year 2025 results presented a study in contrasts. While Agilon Health managed to exceed revenue estimates, the achievement was overshadowed by substantial profitability challenges that have raised questions about the company’s near-term financial trajectory. The revenue performance suggests the company maintains some operational momentum, yet the underlying economics tell a more complicated story.

Profitability metrics paint a concerning picture for investors. Analysts project earnings per share of negative $0.79 for fiscal year 2026 and negative $0.52 for fiscal year 2027, indicating the company will remain unprofitable for at least the next two fiscal years. The company’s gross profit margin stands at negative 2.5% for the last twelve months, highlighting fundamental operational challenges. These projections underscore the significant work ahead for management to achieve positive earnings.

The profitability challenges stem from multiple sources, including risk adjustment impacts and the company’s decision to exit certain markets. Risk adjustment, a mechanism used in Medicare Advantage and other value-based care arrangements to account for patient health status, has created headwinds for the company’s financial performance. The market exits, while potentially strategic for long-term health, have contributed to near-term financial pressure.

Guidance Reestablishment Provides Clarity

In response to the quarter’s results, Agilon Health reestablished its guidance for fiscal year 2025, providing investors with updated expectations. The company projects revenue between $5.81 billion and $5.83 billion for the full year, a range that reflects the company’s scale in the healthcare services market. The revenue guidance suggests the company maintains a substantial business base despite its challenges.

The earnings before interest, taxes, depreciation, and amortization (EBITDA) guidance tells a different story. The company expects EBITDA to range between negative $270 million and negative $245 million for fiscal year 2025, compared to actual EBITDA of negative $374.57 million over the last twelve months. This substantial loss at the EBITDA level highlights the magnitude of the company’s profitability challenges and the distance to achieving breakeven operations. Interestingly, according to InvestingPro analysis, the stock appears undervalued at current levels despite these operational headwinds, with the platform’s Fair Value suggesting significant upside potential. Investors can access detailed valuation metrics and over a dozen additional InvestingPro Tips to better understand AGL’s investment potential.

Cash management has become a critical focus area. Agilon Health expects to end fiscal year 2025 with approximately $310 million in cash. This cash position will be essential for funding operations as the company works through its profitability challenges. Analysts note significant free cash flow burn expected throughout fiscal year 2025, making cash preservation and management paramount.

Reverse Stock Split Plans Signal Strategic Response

The company has announced plans for a reverse stock split, a corporate action that reduces the number of outstanding shares while proportionally increasing the share price. Companies typically pursue reverse stock splits to maintain compliance with exchange listing requirements or to improve the perception of their stock. The decision reflects management’s awareness of the stock’s performance challenges and the need to address technical trading considerations.

Payor Relationships Present Critical Challenge

One of the most significant concerns facing Agilon Health involves its relationships with payors, the insurance companies and health plans that contract with the company for its services. Payor contracting strategies represent a critical factor for the company’s success, as these relationships drive revenue and determine the economic terms under which the company operates.

Analysts have identified notable friction in tone between Agilon Health and one of its large payors. This tension could pose substantial challenges for the company’s business model, which depends on maintaining strong working relationships with health plans. The healthcare services industry requires close collaboration between providers, technology platforms like Agilon Health, and payors to deliver value-based care effectively.

The friction with a major payor raises questions about contract renewals, pricing terms, and the potential for relationship deterioration. In value-based care arrangements, trust and alignment between parties are essential for success. Any breakdown in these relationships could impact the company’s ability to maintain or grow its revenue base.

Industry Dynamics May Provide Relief

Looking beyond company-specific challenges, broader industry dynamics could provide some relief for Agilon Health. Analysts anticipate potential benefit reductions across the industry for the coming year, which could help the sector including Agilon Health. These benefit reductions, while potentially controversial from a patient perspective, could improve the economics for companies operating in value-based care arrangements.

Benefit reductions typically refer to changes in covered services or cost-sharing arrangements that reduce the overall cost of providing care. For companies like Agilon Health that assume financial risk for patient populations, lower benefit levels can translate to improved margins if medical costs decline proportionally. The potential for industry-wide benefit reductions represents one of the few positive catalysts identified by analysts.

The value-based care sector continues to evolve as the healthcare system gradually shifts from fee-for-service to risk-based payment models. This transition creates both opportunities and challenges for companies positioned to enable this shift. Agilon Health’s technology platform and physician partnership model aim to capitalize on this trend, though execution challenges have limited results to date.

Bear Case

Can Agilon Health overcome its profitability challenges and achieve breakeven operations?

The path to profitability appears steep for Agilon Health based on current financial projections. With expected losses of $0.79 per share in fiscal year 2026 and $0.52 per share in fiscal year 2027, the company faces at least two more years of unprofitable operations—a concern echoed by InvestingPro analysis indicating analysts do not anticipate profitability this year. The negative EBITDA guidance of $245 million to $270 million for fiscal year 2025 demonstrates that losses extend beyond just the net income level to core operational performance.

The company’s profitability challenges stem from fundamental business model issues rather than temporary factors. Risk adjustment impacts suggest the company may have difficulty accurately predicting and managing the health status of its patient populations, a core competency required for success in value-based care. Market exits indicate that some of the company’s expansion efforts have not generated acceptable returns, raising questions about the scalability and replicability of the business model.

The significant free cash flow burn expected in fiscal year 2025 compounds these concerns. Cash consumption limits the company’s strategic flexibility and may eventually require additional capital raises that could dilute existing shareholders. With only $310 million expected in cash at year-end fiscal year 2025, the company has limited runway to achieve profitability without accessing additional capital.

Will payor relationship friction impact future revenue and contract renewals?

The identified friction between Agilon Health and one of its large payors represents a substantial risk to the company’s revenue stability. In the healthcare services industry, payor relationships are foundational to business success. Contracts with major health plans typically represent significant portions of revenue, and the loss of a major payor relationship could materially impact financial performance.

The friction in tone suggests deeper issues beyond normal business negotiations. Value-based care arrangements require close collaboration, data sharing, and aligned incentives between payors and provider enablement platforms like Agilon Health. When relationships become strained, it can lead to unfavorable contract terms, reduced referrals, or ultimately contract termination.

The company’s payor contracting strategies are identified as critical for success, making any relationship challenges particularly concerning. If the friction with a major payor leads to contract non-renewal or significantly worse economic terms, it could accelerate the company’s cash burn and delay the path to profitability. The situation also raises questions about whether similar tensions exist with other payors that have not yet become apparent.

Bull Case

Could industry benefit reductions improve margins and accelerate the path to profitability?

Industry-wide benefit reductions anticipated for the coming year could provide meaningful relief for Agilon Health’s financial performance. In value-based care models where companies assume financial risk for patient populations, the cost of providing benefits directly impacts profitability. If benefit levels decline across the industry, it could reduce medical costs without necessarily reducing the revenue Agilon Health receives from payors.

The margin improvement potential from benefit reductions could be substantial. Even modest reductions in benefit costs, when applied across a large patient population, can translate to significant dollar savings. For a company operating at negative EBITDA margins, any improvement in the cost structure moves the company closer to breakeven operations.

Benefit reductions also tend to be industry-wide phenomena, meaning competitors would experience similar dynamics. This levels the competitive playing field and could reduce pressure on pricing as all market participants benefit from improved economics. The anticipated benefit reductions represent one of the few external tailwinds identified for the company and could help offset some of the company-specific challenges.

Does revenue performance exceeding estimates signal underlying business strength?

Agilon Health’s ability to exceed revenue estimates in the third quarter fiscal year 2025 suggests the company maintains operational momentum despite its profitability challenges. Revenue growth indicates the company continues to add physician partners, expand into new markets, or increase the number of patients under management. This top-line performance demonstrates that the company’s value proposition resonates with physician groups seeking to participate in value-based care.

The reestablishment of guidance provides clarity and suggests management has visibility into the business trajectory. By setting specific revenue targets of $5.81 billion to $5.83 billion for fiscal year 2025, management signals confidence in the revenue-generating capabilities of the business. This scale demonstrates that Agilon Health has built a substantial platform in the healthcare services market.

Revenue growth also provides operating leverage opportunities. As the company scales, fixed costs can be spread across a larger revenue base, potentially improving margins over time. If the company can maintain revenue growth while controlling costs and improving risk adjustment accuracy, the path to profitability becomes more achievable. The revenue performance suggests the business model has market acceptance even as execution challenges persist.

SWOT Analysis

Strengths

• Revenue performance exceeding analyst estimates demonstrates continued business growth
• Reestablished guidance provides clarity and visibility for investors
• Substantial revenue scale with projected fiscal year 2025 revenue between $5.81 billion and $5.83 billion
• Technology-enabled platform serving physician groups in value-based care arrangements

Weaknesses

• Unprofitable operations with negative earnings per share projected for at least two fiscal years
• Significant EBITDA losses expected between $245 million and $270 million for fiscal year 2025
• Substantial free cash flow burn throughout fiscal year 2025
• Risk adjustment impacts negatively affecting profitability
• Market exits indicating some expansion efforts have not succeeded
• Limited cash position of approximately $310 million expected at end of fiscal year 2025

Opportunities

• Potential industry benefit reductions could improve margins and profitability
• Ongoing healthcare industry transition from fee-for-service to value-based care models
• Margin improvement potential as the company scales operations
• Ability to leverage technology platform across growing physician partner base

Threats

• Friction with major payor could impact contract renewals and revenue stability
• Payor contracting challenges critical to business model success
• Continued profitability pressures may require additional capital raises
• Competitive pressures in the value-based care enablement market
• Execution risks in managing patient populations and risk adjustment

Analyst Targets

• Citi Research (Citizens Bank) - November 6, 2025: Market Perform rating, no price target specified
• Barclays Capital Inc. - November 6, 2025: Underweight rating, price target $1.00

This analysis is based on information available through November 6, 2025. For investors seeking deeper insights into AGL’s financial health and future prospects, the company is one of 1,400+ US equities covered by comprehensive Pro Research Reports, which transform complex Wall Street data into clear, actionable intelligence through intuitive visuals and expert analysis.

InvestingPro: Smarter Decisions, Better Returns

Gain an edge in your investment decisions with InvestingPro’s in-depth analysis and exclusive insights on AGL. Our Pro platform offers fair value estimates, performance predictions, and risk assessments, along with additional tips and expert analysis. Explore AGL’s full potential at InvestingPro.

Should you invest in AGL right now? Consider this first:

Investing.com’s ProPicks, an AI-driven service trusted by over 130,000 paying members globally, provides easy-to-follow model portfolios designed for wealth accumulation. Curious if AGL is one of these AI-selected gems? Check out our ProPicks platform to find out and take your investment strategy to the next level.

To evaluate AGL further, use InvestingPro’s Fair Value tool for a comprehensive valuation based on various factors. You can also see if AGL appears on our undervalued or overvalued stock lists.

These tools provide a clearer picture of investment opportunities, enabling more informed decisions about where to allocate your funds.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.